The AMNOG-Monitor provides all relevant information on early benefit assessment and price negotiations, updated daily. A solid foundation for Market Access, HTA, Medical, Business Development, and Pricing.
10. July 2026
On Friday, 10 July 2026, in the last session before the summer break, the Bundestag and the Bundesrat passed the Statutory Health Insurance Contribution Rate Stabilisation Act (GKV-Beitragssatzstabilisierungsgesetz, BStabG) with …
08. July 2026
The two procedures relate to Pharma Mar's Zepzelca (lurbinectedin) and Amgen's Imdylltra (tarlatamab), both for the treatment of extensive-stage small cell lung cancer (ES-SCLC), for which randomised controlled trials had …
02. July 2026
The Federal Joint Committee (G-BA) has decided today which impartial member will chair each of the currently ten subcommittees until the end of the current term in 2030:
Key data from all AMNOG decisions, summarized in a compact and structured format.
Analyze your own research questions by filtering across more than 120 parameters.
Fast, quality-assured analysis of original documents such as dossiers, G-BA decisions, arbitration rulings, and clinical trials.
Price trends for all AMNOG drugs at PZN level and for annual therapy costs. Tracking of all appropriate comparator therapies (ZVT) and their weighting (on request).
EU dossiers and JCAs will be integrated into the AMNOG-Monitor as soon as the first ones become available.
Export analysis results to Excel, PowerPoint, or Word with links back to the AMNOG-Monitor. Save standard queries for price changes or new indications using bookmarks.
